 |
|
|
| |
CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist
|
| |
| |
Reported by Jules Levin
IAC Aug 3-8 2008 Mexico City
Andre J Marozsan
Progenics Pharmaceuticals, Inc.
AUTHOR SUMMARY
A virus resistant to maravirocwas generated in PBMC culture over 31 weeks of passage.
The maravirocescape virus remained R5; however, the passage control virus became R5X4.
The maravirocescape virus displayed similar phenotype and sequence to one generated by Pfizer.
For Case C 1/85, maravirocresistance did not confer cross-resistance to PRO 140.
Acknowledgements
Progenics Pharmaceuticals, Inc.
Tom Ketas
William Olson, Ph.D.
Paul Maddon, M.D., Ph.D.
Monogram Biosciences, Inc.
Wei Huang, Ph.D.
Jonathan Toma, Ph.D.
Jeannette Whitcomb, Ph.D.
Chris Petropoulos, Ph.D.
This study was supported by Public Health Service award AI066329 from the National Institute of Allergy and Infectious Diseases
|
| |
|
|
|
|
|
